These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12456201)

  • 21. Sample size determination for cost-effectiveness trials.
    Willan AR
    Pharmacoeconomics; 2011 Nov; 29(11):933-49. PubMed ID: 21988292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic analysis of randomized, controlled trials.
    Lyman GH
    Curr Oncol Rep; 2001 Sep; 3(5):396-403. PubMed ID: 11489239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
    Baltussen R; Leidl R; Ament A
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size.
    Campbell MK; Mollison J; Grimshaw JM
    Stat Med; 2001 Feb; 20(3):391-9. PubMed ID: 11180309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?
    Stevens JW
    Pharmacoeconomics; 2018 Oct; 36(10):1135-1141. PubMed ID: 29926358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses.
    Müller D; Pullenayegum E; Gandjour A
    Eur J Health Econ; 2015 Mar; 16(2):219-23. PubMed ID: 24840608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive algorithm for determining whether a run-in strategy will be a cost-effective design modification in a randomized clinical trial.
    Schechtman KB; Gordon ME
    Stat Med; 1993 Jan; 12(2):111-28. PubMed ID: 8446807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study.
    Teare MD; Dimairo M; Shephard N; Hayman A; Whitehead A; Walters SJ
    Trials; 2014 Jul; 15():264. PubMed ID: 24993581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Power and sample size for cost-effectiveness analysis: fFN neonatal screening.
    Boyd KA; Briggs AH; Fenwick E; Norrie J; Stock S
    Contemp Clin Trials; 2011 Nov; 32(6):893-901. PubMed ID: 21782976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical versus quantitative significance in the socioeconomic evaluation of medicines.
    O'Brien BJ; Drummond MF
    Pharmacoeconomics; 1994 May; 5(5):389-98. PubMed ID: 10147230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group.
    Everest L; Chen BE; Hay AE; Cheung MC; Chan KKW
    BMC Med Res Methodol; 2023 Aug; 23(1):179. PubMed ID: 37537545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials.
    Detsky AS
    Stat Med; 1990; 9(1-2):173-84. PubMed ID: 2111932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.
    Walter SD; Gafni A; Birch S
    Pharmacoeconomics; 2007; 25(6):455-66. PubMed ID: 17523751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing a cost-effective clinical trial.
    Hornberger JC; Brown BW; Halpern J
    Stat Med; 1995 Oct; 14(20):2249-59. PubMed ID: 8552901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size calculation in cost-effectiveness cluster randomized trials: optimal and maximin approaches.
    Manju MA; Candel MJ; Berger MP
    Stat Med; 2014 Jul; 33(15):2538-53. PubMed ID: 25019136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unequal randomisation can improve the economic efficiency of clinical trials.
    Torgerson D; Campbell M
    J Health Serv Res Policy; 1997 Apr; 2(2):81-5. PubMed ID: 10180369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Costing and cost analysis in randomized controlled trials: caveat emptor.
    Polsky D; Glick H
    Pharmacoeconomics; 2009; 27(3):179-88. PubMed ID: 19354338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cluster randomized trials: another problem for cost-effectiveness ratios.
    Flynn TN; Peters TJ
    Int J Technol Assess Health Care; 2005; 21(3):403-9. PubMed ID: 16110722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empirical analysis shows reduced cost data collection may be an efficient method in economic clinical trials.
    Seidl H; Meisinger C; Wende R; Holle R
    BMC Health Serv Res; 2012 Sep; 12():318. PubMed ID: 22978572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do randomized controlled trials discuss healthcare costs?
    Allan GM; Korownyk C; LaSalle K; Vandermeer B; Ma V; Klein D; Manca D
    PLoS One; 2010 Aug; 5(8):e12318. PubMed ID: 20808794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.